Impact of the COVID-19 pandemic on hospitalizations with hepatocellular carcinoma in the United States.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-01-01 Epub Date: 2024-02-19 DOI:10.1080/17474124.2024.2319580

Peter Konyn, Brandon J Perumpail, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed, Donghee Kim

{"title":"Impact of the COVID-19 pandemic on hospitalizations with hepatocellular carcinoma in the United States.","authors":"Peter Konyn, Brandon J Perumpail, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed, Donghee Kim","doi":"10.1080/17474124.2024.2319580","DOIUrl":null,"url":null,"abstract":"Background: We studied the temporal trends of hepatocellular carcinoma (HCC)-related hospitalizations and potential predictors of in-hospital mortality around the COVID-19 pandemic.Research design and methods: Using the International Classification of Diseases code, we used the National Inpatient Sample 2019-2020 and defined HCC and its underlying etiology. To assess the impact of the COVID-19 pandemic on hospitalization and in-hospital mortality, the study period was divided into the pre-COVID-19 era (2019 Q1-2020 Q1) and the COVID-19 era (2020 Q2-2020 Q4). Quarterly trends in etiology-based hospitalizations with HCC and predictors of in-hospital mortality among hospitalizations with HCC were determined.Results: Hospitalization rates for HCC, as well as viral hepatitis-related HCC hospitalization rates, remained stable, while hospitalizations with alcohol-related liver disease (ALD, quarterly percentage change [QPC]: 2.1%; 95% confidence interval [CI]: 0.1%-4.2%) increased steadily. Hospitalization related to nonalcoholic fatty liver disease (NAFLD)-related HCC increased significantly steeper in the COVID-19 era (QPC: 6.6%; 95% CI: 4.0%-9.3%) than in the pre-COVID-19 era (QPC: 0.7%; 95% CI: 0.2%-1.3%). COVID-19 infection was independently associated with in-hospital mortality among hospitalizations with HCC (odds ratio: 1.94, 95% CI: 1.30-2.88).Conclusion: Hospitalization rates for viral hepatitis-related HCC remained stable, while those for HCC due to ALD and NAFLD increased during the COVID-19 pandemic.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"113-119"},"PeriodicalIF":3.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2319580","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We studied the temporal trends of hepatocellular carcinoma (HCC)-related hospitalizations and potential predictors of in-hospital mortality around the COVID-19 pandemic.

Research design and methods: Using the International Classification of Diseases code, we used the National Inpatient Sample 2019-2020 and defined HCC and its underlying etiology. To assess the impact of the COVID-19 pandemic on hospitalization and in-hospital mortality, the study period was divided into the pre-COVID-19 era (2019 Q1-2020 Q1) and the COVID-19 era (2020 Q2-2020 Q4). Quarterly trends in etiology-based hospitalizations with HCC and predictors of in-hospital mortality among hospitalizations with HCC were determined.

Results: Hospitalization rates for HCC, as well as viral hepatitis-related HCC hospitalization rates, remained stable, while hospitalizations with alcohol-related liver disease (ALD, quarterly percentage change [QPC]: 2.1%; 95% confidence interval [CI]: 0.1%-4.2%) increased steadily. Hospitalization related to nonalcoholic fatty liver disease (NAFLD)-related HCC increased significantly steeper in the COVID-19 era (QPC: 6.6%; 95% CI: 4.0%-9.3%) than in the pre-COVID-19 era (QPC: 0.7%; 95% CI: 0.2%-1.3%). COVID-19 infection was independently associated with in-hospital mortality among hospitalizations with HCC (odds ratio: 1.94, 95% CI: 1.30-2.88).

Conclusion: Hospitalization rates for viral hepatitis-related HCC remained stable, while those for HCC due to ALD and NAFLD increased during the COVID-19 pandemic.

查看原文本刊更多论文

COVID-19 大流行对美国肝细胞癌住院治疗的影响。

研究背景我们研究了COVID-19大流行前后肝细胞癌（HCC）相关住院的时间趋势以及院内死亡率的潜在预测因素：通过国际疾病分类代码，我们使用了2019-2020年全国住院患者样本，并定义了HCC及其基本病因。为了评估 COVID-19 大流行对住院治疗和住院死亡率的影响，我们将研究期间分为前 COVID-19 时代（2019 年第一季度-2020 年第一季度）和 COVID-19 时代（2020 年第二季度-2020 年第四季度）。研究确定了基于病因的 HCC 住院率的季度趋势以及 HCC 住院死亡率的预测因素：结果：HCC 的住院率以及病毒性肝炎相关的 HCC 住院率保持稳定，而酒精相关肝病（ALD，季度百分比变化 [QPC]：2.1%；95% 置信区间 [CI]：0.1%-4.2%）的住院率保持稳定：0.1%-4.2%）稳步上升。与非酒精性脂肪肝（NAFLD）相关的 HCC 住院率在 COVID-19 时代（QPC：6.6%；95% 置信区间 [CI]：4.0%-9.3%）比 COVID-19 前时代（QPC：0.7%；95% 置信区间 [CI]：0.2%-1.3%）显著增加。COVID-19感染与HCC住院患者的院内死亡率独立相关（几率比：1.94，95% CI：1.30-2.88）：结论：在 COVID-19 大流行期间，病毒性肝炎相关 HCC 的住院率保持稳定，而 ALD 和非酒精性脂肪肝导致的 HCC 住院率则有所上升。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.